Browse Articles
Discover research articles across all indexed journals
Study of physiochemical properties of trisubstituted pyrazole derivatives using polar aprotic solvents
Livedo Racemosa
Sex-specific response of intramuscular fat to diet-induced obesity in rats
Challenges to the Future of a Robust Physician Workforce in the United States
Author Correction: Design of retrofit flue gas (CO2) scrubber for dependable clean energy at the Duvha Coal Power Plant
Burnout, Depression, and Diminished Well-Being among Physicians
B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer
Finerenone in Heart Failure with Preserved Ejection Fraction
Comparison of management options for spontaneous bleeding into soft tissues in patients with COVID-19
Case 2-2025: A 21-Year-Old Man with Loss of Consciousness and a Fall
High-resolution X-ray phase-contrast tomography of human placenta with different wavefront markers
Abstract Phase-contrast micro-tomography ( $$\upmu$$ CT) with synchrotron radiation can aid in the differentiation of subtle density variations in weakly absorbing soft tissue specimens. Modulation-based imaging (MBI) extracts phase information from the distortion of reference patterns, generated by periodic or randomly structured wavefront markers (e.g., gratings or sandpaper). The two approaches have already found application for the virtual inspection of biological samples. Here, we perform high-resolution $$\upmu$$ CT scans of an unstained human placenta specimen, using MBI with both a 2D grating and sandpaper as modulators, as well as conventional propagation-based imaging (PBI). The 3D virtual representation of placenta offers a valuable tool for analysing its intricate branching villous network and vascular structure, providing new insights into its complex architecture. Within this study, we assess reconstruction quality achieved with all three evaluated phase-contrast methods. Both MBI datasets are processed with the Unified Modulated Pattern Analysis (UMPA) model, a pattern-matching algorithm. In order to evaluate the benefits and suitability of MBI for virtual histology, we discuss how the complexities of the technique influence image quality and correlate the obtained volumes to 2D techniques, such as conventional histology and X-ray fluorescence (XRF) elemental maps.
Centrophilic retrotransposon integration via CENH3 chromatin in Arabidopsis
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age
A hybrid critical channels and optimal feature subset selection framework for EEG fatigue recognition
Publisher Correction: Preliminary investigation on the establishment of a new meibomian gland obstruction model and gene expression
Self-referential belief shares common neural correlates with general belief
Abstract Belief processing and self-referential processing have been consistently associated with cortical midline structures, and cortical regions such as the vmPFC have been implicated in general belief processing. The neural correlates of self-referential belief are yet to be investigated. In this fMRI study, we presented 120 statements with trait adjectives to N = 27 healthy participants, who subsequently judged whether they believed these trait adjectives applied to themselves, a close person, or a public person. Thereafter, participants rated their certainty in this judgment. Expectedly, self-referential processing evoked a large cluster in the vmPFC, ACC, and dmPFC. For belief, we found a cluster in the vmPFC, ACC, and amPFC during statement presentation, partially overlapping with that for self-referential processing. The cluster for self-belief vs. disbelief was similar in location and size to that for general belief processing. For uncertainty, we found dmPFC activation. We replicated vmPFC involvement in belief processing and found a common neural correlate for belief and self-belief in the vmPFC. Furthermore, we replicated the role of the dmPFC in uncertainty, supporting a dual neural process model of belief and certainty.
HLA-I aberrations in cutaneous T-cell lymphoma
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Abstract No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study evaluating D-R vs R maintenance in patients with newly diagnosed multiple myeloma (NDMM) who had very good or better partial response, were minimal residual disease (MRD)-positive (10–5) and anti-CD38–naïve after transplant. Two hundred patients were randomly assigned (1:1) to D-R (n = 99) or R (n = 101) maintenance for up to 36 cycles. The MRD-negative (10–5) conversion rate by 12 months from start of maintenance (primary end point) was significantly higher for D-R than R (50.5% vs 18.8%; odds ratio [OR], 4.51; 95% confidence interval [CI], 2.37-8.57; P < .0001). MRD-negative (10–6) conversion rate was similarly higher with D-R (23.2% vs 5.0%; OR, 5.97; 95% CI, 2.15-16.58; P = .0002). At median follow-up (32.3 months), D-R achieved a higher overall MRD-negative (10–5) conversion rate (D-R, 60.6% vs R, 27.7%; OR, 4.12; 95% CI, 2.26-7.52; P < .0001) and complete response rate or better (75.8% vs 61.4%; OR, 2.00; 95% CI, 1.08-3.69; P = .0255) vs R. Progression-free survival (PFS) favored D-R vs R (hazard ratio, 0.53; 95% CI, 0.29-0.97); estimated 30-month PFS rates were 82.7% for D-R and 66.4% for R. Incidences of grade 3/4 cytopenias (54.2% vs 46.9%) and infections (18.8% vs 13.3%) were slightly higher with D-R than R. In conclusion, D-R maintenance achieved a higher MRD-negative conversion rate and improved PFS after transplant vs R, with no new safety concerns. This trial was registered at www.clinicaltrials.gov as #NCT03901963.
Genetic alteration of class I HLA in cutaneous T-cell lymphoma
Abstract Abnormalities involving class I HLA are frequent in many lymphoma subtypes but have not yet been extensively studied in cutaneous T-cell lymphomas (CTCLs). We characterized the occurrence of class I HLA abnormalities in 65 patients with advanced mycosis fungoides or Sézary syndrome. Targeted DNA sequencing, including coverage of HLA loci, revealed at least 1 HLA abnormality in 26 of 65 patients (40%). Twelve unique somatic HLA mutations were identified across 9 patients, and loss of heterozygosity or biallelic loss of HLA was found to affect 24 patients. Although specific HLA alleles were commonly disrupted, these events did not associate with a decrease in the total class I HLA expression. Genetic events preferentially disrupted HLA alleles capable of presenting greater numbers of putative neoantigens. HLA abnormalities co-occurred with other genetic immune evasion events and were associated with worse progression-free survival. Single-cell analyses demonstrated that HLA abnormalities were frequently subclonal. Through analysis of serial samples, we observed that disrupting class I HLA events change dynamically over the disease course. The dynamics of HLA disruption are highlighted in a patient who received pembrolizumab and in whom resistance to pembrolizumab was associated with the elimination of an HLA mutation. Overall, our findings show that genomic class I HLA abnormalities are common in advanced CTCL and may be an important consideration in understanding the effects of immunotherapy in CTCL.